BRCA1 and ovarian carcinoma: For example, CRISPR-Cas9 introduction of Trp53, Brca1, Nf1, and Pten mutations in OSE and FTE organoids were used to confirm the origin of HGSOC [154], and TP53 and RB1 knockout was used to study their impact in patient-derived ovarian cancer organoids [39].